Corvus Pharmaceuticals, Inc. (CRVS): Operating Cash Flow
-$32.80M
Year ended 2025-12-31
-$44.53M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$32.80M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$25.42M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$23.93M | n/m | 2026-03-12, From 2023-01-01 |
| 2022-12-31 | -$27.02M | n/m | 2025-03-25, From 2022-01-01 |
| 2021-12-31 | -$36.72M | n/m | 2024-03-19, From 2021-01-01 |
| 2020-12-31 | -$34.78M | n/m | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | -$37.32M | n/m | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | -$40.99M | n/m | 2021-03-25, From 2018-01-01 |
| 2017-12-31 | -$46.21M | n/m | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | -$27.86M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | -$11.33M | n/a | 2018-03-01, From 2015-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | -$32.80M | n/m |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | -$33.35M | n/m |
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | -$60.29M | n/m |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | -$12.87M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | -$12.62M | n/m |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | -$26.39M | n/m |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | -$88.63M | n/m |
| Grace Therapeutics, Inc. (GRCE) | 2026-03-31 | -$8.87M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.93M | n/m |
Compare CRVS, ALDX, HOWL, IXHL side by side · Screen every company in Pharmaceutical Preparations ↗